… Our study showed that nirmatrelvir-ritonavir was associated with decreased SARS-CoV-2 …
, we found that nirmatrelvir-ritonavir use could also reduce the length of hospital stay. These …

… of Molnupiravir and Nirmatrelvir-ritonavir use in reducing mortality in this population. … risk
of hospitalization or deaths. Recent real work data in Israel shows that Nirmatrelvir-Ritonavir is …

… effectiveness against more recent omicron subvariants of SARS-CoV-2, we used our real-world
data platform to evaluate the effect of nirmatrelvir–ritonavir treatment on 28-day …

… over a mean follow-up of 41.3 days with 925,713 person-days, this study included 1,856
molnupiravir users, 890 nirmatrelvir/ritonavir users and 2,746 control patients not initially …

… 800 mg molnupiravir twice per day for 5 days, and 880 (98·9%) nirmatrelvir–ritonavir recipients
completed the 5 day regimen of 300 mg nirmatrelvir and 100 mg ritonavir twice per day. …

… had a shorter length of hospital stay (HR 3.573, p = … treatment with Nirmatrelvir/Ritonavir
within 5 days of diagnosis (≤5 days) was highly effective in shortening the length of hospital …

… Our objective was to evaluate the effectiveness of nirmatrelvir–ritonavir on health outcomes,
including hospital admission and death from COVID-19, while Omicron and its subvariants …

… by Nirmatrelvir‐ritonavir therapy.Currently, there are limited reports about the effect of
Nirmatrelvir‐ritonavir … This study aimed to determine the effects of Nirmatrelvirritonavir therapy and …

… In this retrospective cohort study, we sought to compare the effectiveness of sotrovimab,
molnupiravir, and nirmatrelvir-ritonavir in preventing hospital admission and death in higher-risk …

… medical personnel in an in‐hospital setting may limit the use of these … , nirmatrelvir–ritonavir
(Paxlovid™), for the treatment of … the efficacy and safety of nirmatrelvir–ritonavir in COVID‐19 …